AARD Overview

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Wall Street analysts forecast AARD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AARD is33.00 USD with a low forecast of 18.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aardvark Therapeutics Inc revenue for the last quarter amounts to -17.70M USD, increased 247.73

Aardvark Therapeutics Inc. EPS for the last quarter amounts to -16134000.00 USD, increased 307.42

Aardvark Therapeutics Inc (AARD) has 22 emplpoyees as of February 28 2026.

Today AARD has the market capitalization of 271.95M USD.